Bevacizumab (Avastin; Genentech), a humanized monoclonal antibody directed against VEGF-A and the most studied of the anti-VEGF-A/VEGFR drugs, prolongs the life of patients with advanced colon cancer by only 4–5 months and then only when accompanied by chemotherapy [8]. The gene discussed is VEGFA; the disease is colonic neoplasm.